Key result
Adequate antithrombotic therapy, particularly the early administration of clopidogrel, significantly reduces mortality in patients with acute coronary syndromes based on international clinical trials.
Why the study?
Does adequate antithrombotic therapy reduce mortality in patients with acute coronary syndromes?
Does adequate antithrombotic therapy reduce mortality in patients with acute coronary syndromes?
Early and comprehensive antithrombotic therapy is essential for reducing mortality in patients presenting with acute coronary syndromes.
May support early clopidogrel in ACS; leaves open confirmation in contemporary RCTs.
The article considers adequate antithrombotic therapy in acute coronary syndromes, which on the basis of evidence-based medicine makes it possible to significantly reduce mortality in patients. At the present stage, the application of clopidogrel requires its earliest prescription to the patients during their first visit to the doctor with the account of forthcoming percutaneous coronary surgery.
No takes yet. Share an insight, caveat, or question.
D. P. Salivonchyk (2013) conducted a review in Acute coronary syndromes. Antithrombotic therapy (including clopidogrel) was evaluated. Adequate antithrombotic therapy, particularly the early administration of clopidogrel, significantly reduces mortality in patients with acute coronary syndromes based on international clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: